| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 333,931 | 201,532 | ||
| Rent receivable | 87,317 | 84,893 | ||
| Receivable from sale of equity method investment | 1,028,500 | - | ||
| Prepaid expense and other current assets | 639,285 | 646,663 | ||
| Total current assets | 2,089,033 | 933,088 | ||
| Operating lease right-of-use assets, net | 83,490 | 98,595 | ||
| Property and equipment, net | 6,355 | 8,512 | ||
| Investment in real estate, net | 6,932,074 | 6,938,380 | ||
| Equity method investments, net | - | 0 | ||
| Other non-current assets | 17,503 | 9,581 | ||
| Total non-current assets | 7,039,422 | 7,055,068 | ||
| Total assets | 9,128,455 | 7,988,156 | ||
| Accrued professional fees | 1,320,286 | 1,583,799 | ||
| Accrued research and development fees | 153,772 | - | ||
| Accrued payroll liability and compensation | 827,524 | 733,669 | ||
| Accrued litigation settlement | 363,450 | 373,450 | ||
| Accrued liabilities and other payables | 201,067 | 306,077 | ||
| Accrued liabilities and other payables - related parties-Related Party | 100,000 | 100,000 | ||
| Operating lease obligation, current portion | 71,691 | 69,573 | ||
| Advance from pending sale of noncontrolling interest - related party | 3,158,078 | - | ||
| Derivative liability | 100,423 | 125,553 | ||
| Stock subscription liability | 150,000 | - | ||
| Note payable, net | 5,797,466 | 5,775,061 | ||
| Stock subscription liability | - | 150,000 | ||
| Advance from pending sale of noncontrolling interest - related party-Related Party | - | 3,258,078 | ||
| Accrued research and development fees | - | 153,772 | ||
| Convertible note payable, net | 1,359,918 | 2,436,375 | ||
| Total current liabilities | 13,603,675 | 15,065,407 | ||
| Operating lease obligation, noncurrent portion | 17,799 | 35,022 | ||
| Total non-current liabilities | 17,799 | 35,022 | ||
| Total liabilities | 13,621,474 | 15,100,429 | ||
| Preferred stock, value-Series CPreferred Stock | 3,790,000 | 3,500,000 | ||
| Preferred stock, value-Series BPreferred Stock | - | 0 | ||
| Preferred stock, value-Series APreferred Stock | - | 0 | ||
| Preferred stock, value | - | 0 | ||
| Preferred stock, value-Series DPreferred Stock | 8,837,527 | 8,837,527 | ||
| Common stock, 0.0001 par value 100,000,000 shares authorized 4,100,576 shares issued and 4,097,109 shares outstanding at september 30, 2025 1,445,979 shares issued and 1,442,512 shares outstanding at december 31, 2024 | 410 | 235 | ||
| Additional paid-in capital | 87,494,414 | 84,911,338 | ||
| Less common stock held in treasury, at cost 3,467 shares at september 30, 2025 and december 31, 2024 | 522,500 | - | ||
| Less common stock held in treasury, at cost 3,467 shares at june 30, 2025 and december 31, 2024 | - | 522,500 | ||
| Accumulated deficit | -103,868,102 | -103,613,834 | ||
| Statutory reserve | 6,578 | 6,578 | ||
| Accumulated other comprehensive loss | -231,346 | -231,617 | ||
| Total avalon globocare corp. stockholders (deficit) equity | -4,493,019 | -7,112,273 | ||
| Noncontrolling interest | - | 0 | ||
| Total (deficit) equity | -4,493,019 | -7,112,273 | ||
| Total liabilities and (deficit) equity | 9,128,455 | 7,988,156 | ||
Avalon GloboCare Corp. (ALBT)
Avalon GloboCare Corp. (ALBT)